Motor Symptoms of Schizophrenia
Schizophrenia is intrinsically associated with multiple motor abnormalities that occur both spontaneously as part of the disease and as medication side effects, including extrapyramidal symptoms, tardive dyskinesia, catatonia, and neurological soft signs. 1
Primary Motor Manifestations
Spontaneous Motor Abnormalities (Disease-Related)
Catatonia is now recognized as a distinct syndrome of psychomotor disturbances rather than a subtype of schizophrenia, characterized by stupor, catalepsy, waxy flexibility, mutism, negativism, posturing, mannerisms, stereotypies, psychomotor agitation, grimacing, echolalia, and echopraxia 2. Catatonia significantly impairs both global and social functioning, with patients scoring substantially lower on functional outcome measures compared to those without catatonia 3.
Neurological soft signs represent subtle motor coordination and sensory integration abnormalities that are frequently observed across all stages of schizophrenia, including in subjects at clinical or genetic risk for psychosis 4, 5. These signs correlate negatively with social functioning 3.
Psychomotor slowing is a hypokinetic motor abnormality that correlates with reduced physical activity levels and worse functional outcomes across multiple assessment scales 3, 6.
Medication-Induced Motor Abnormalities
Acute Extrapyramidal Side Effects
Dystonia involves sudden spastic contractions of distinct muscle groups, most commonly affecting the neck, eyes (oculogyric crisis), or torso 1. Risk factors include young age, male gender, and use of high-potency antipsychotic agents 1. Laryngospasm can be life-threatening 1. These reactions typically respond well to anticholinergic or antihistaminic medications 1.
Drug-induced Parkinsonism manifests as bradykinesia, tremors, and rigidity due to antidopaminergic effects 1. This condition is associated with significantly lower scores on global and social functioning scales 3. Treatment involves anticholinergic agents or mild dopaminergic agents like amantadine 1. A critical clinical pitfall is differentiating parkinsonian side effects from negative symptoms of schizophrenia itself or severe catatonia 1.
Akathisia presents as severe restlessness frequently manifested by pacing or physical agitation 1. This is commonly misinterpreted as psychotic agitation or anxiety and represents a major cause of medication noncompliance 1. Treatment is challenging—lowering the antipsychotic dose should be attempted when clinically feasible 1. Antiparkinsonian agents are inconsistently helpful, though β-blockers and benzodiazepines have shown benefit 1.
Tardive Movement Disorders
Tardive dyskinesia (TD) is an involuntary movement disorder typically consisting of athetoid or choreic movements in the orofacial region, though it can affect any body part 1. This represents a major public health concern with significant clinical and medicolegal implications 1. As many as 50% of youth receiving neuroleptics may experience some form of tardive or withdrawal dyskinesia 1. Withdrawal dyskinesias almost always resolve over time, whereas TD may persist even after antipsychotic discontinuation 1.
Because there is no specific treatment for TD other than discontinuing the medication, prevention and early detection strategies are essential 1. Baseline measures of abnormal movements must be recorded before initiating neuroleptic therapy 1. Assessment for dyskinesias should occur at least every 3 to 6 months using standardized instruments like the Abnormal Involuntary Movement Scale 1.
Tardive dystonia is characterized by slow movements along the long axis of the body culminating in spasms, with facial spasms also noted 1. It can be quite disabling and is often associated with tardive dyskinesia 1. The same management strategies used for tardive dyskinesia apply to tardive dystonia 1.
Clinical Significance and Functional Impact
Motor abnormalities in schizophrenia are strongly associated with poor social and functional outcomes 3. The severity of motor impairment directly correlates with worse global and social functioning—the stronger the motor impairment, the worse the community functioning 3. Up to 50% of patients with schizophrenia suffer from motor abnormalities, which contribute to decreased quality of life, impaired work capacity, and reduced life expectancy by 10-20 years 3.
Motor abnormalities are associated with distinct symptom dimensions and may indicate poor outcomes 4. Lower physical activity levels, as measured objectively by actigraphy, correlate with increased severity of both catatonia and parkinsonism 6.
Management Approach
Prophylactic antiparkinsonian agents may be considered to avoid acute extrapyramidal symptoms, especially in patients at risk for acute dystonias, those with a history of dystonic reactions, or when compliance may be an issue (e.g., paranoid patients who distrust medication) 1. However, the need for antiparkinsonian agents should be reevaluated after the acute treatment phase or if doses are lowered, as many patients no longer require them during long-term therapy 1.
When TD occurs, continue the medication at the current dose only if the patient is in full remission and any dosage change would likely precipitate relapse 1. Otherwise, attempt to lower the dose or switch to another medication, most likely an atypical antipsychotic 1. Clozapine has shown beneficial effects on motor phenomena 7.